Skip to main content
Fibrosis Facts
100 Facts About Liver Fibrosis
Definition & Basics
-
Liver fibrosis is the buildup of scar tissue in the liver from ongoing injury.
-
It is a repair process that becomes harmful when injury is chronic.
-
Fibrosis is not a single disease but a shared response across many liver conditions.
-
The medical root "fibro-" refers to fibrous scar tissue.
-
Scar tissue is made mostly of collagen.
-
Fibrosis exists on a spectrum from none to cirrhosis.
-
Cirrhosis is the most advanced, severe stage of fibrosis.
-
Fibrosis stage is the strongest predictor of long-term liver outcomes.
-
Earlier-stage fibrosis can be reversible if the cause is treated.
-
Fibrosis is distinct from inflammation, which is the injury response that often drives it.
The Cells & Biology
-
Hepatic stellate cells are the main drivers of fibrosis.
-
When activated, stellate cells produce excess collagen.
-
The extracellular matrix is the protein scaffolding that expands during fibrosis.
-
Normal liver has a delicate matrix; fibrosis distorts it.
-
Chronic inflammation typically precedes and drives scarring.
-
Immune signaling molecules (cytokines) help activate fibrosis.
-
Oxidative stress contributes to the injury that leads to scarring.
-
The liver has a strong regenerative capacity, but chronic injury overwhelms it.
-
Fibrosis reflects an imbalance between scar formation and scar breakdown.
-
Specialized enzymes can break down scar tissue when injury stops.
Causes
-
Metabolic fatty liver disease (NASH/MASH) is a leading cause of fibrosis.
-
Chronic hepatitis C is a major global cause.
-
Chronic hepatitis B is another leading worldwide cause.
-
Chronic heavy alcohol use is a major cause.
-
Autoimmune hepatitis can cause progressive fibrosis.
-
Primary sclerosing cholangitis (PSC) causes biliary fibrosis.
-
Primary biliary cholangitis (PBC) causes biliary fibrosis.
-
Hemochromatosis (iron overload) can lead to fibrosis.
-
Wilson's disease (copper overload) can cause fibrosis.
-
Certain medications and toxins can injure the liver and cause scarring.
-
Multiple causes can combine and accelerate fibrosis.
-
Bile duct obstruction can lead to fibrosis over time.
Risk Factors & Progression Drivers
-
Type 2 diabetes is linked to faster fibrosis progression.
-
Obesity accelerates fibrosis, especially in metabolic liver disease.
-
Insulin resistance contributes to progression.
-
Genetic variants like PNPLA3 influence progression risk.
-
Older age is associated with faster progression in many conditions.
-
Male sex is associated with higher progression risk in some diseases.
-
Ongoing alcohol use accelerates fibrosis across liver diseases.
-
Coexisting liver conditions raise progression risk.
-
Poorly controlled metabolic health speeds progression.
-
High viral load in untreated hepatitis can drive faster scarring.
How It Progresses
-
Fibrosis usually develops slowly, over years.
-
Progression rates vary widely between individuals.
-
"Bridging fibrosis" describes scar tissue connecting regions of the liver.
-
Advancing fibrosis distorts the liver's internal architecture.
-
Scarring impedes normal blood flow through the liver.
-
Portal hypertension (raised pressure in liver blood vessels) results from advanced scarring.
-
Fibrosis can progress silently, without symptoms.
-
Not everyone with fibrosis progresses to cirrhosis.
Staging
-
Fibrosis is described in stages, commonly F0 to F4.
-
The METAVIR system is a widely used staging scale.
-
F0 means no fibrosis.
-
F1 means mild fibrosis without bridging.
-
F2 means moderate fibrosis with early bridging.
-
F3 means advanced fibrosis with bridging, but not cirrhosis.
-
F4 means cirrhosis.
-
"Significant fibrosis" generally means F2 or higher.
-
"Advanced fibrosis" generally means F3–F4.
-
The Ishak system is another staging scale, often used in research.
-
Staging reflects scarring; grading reflects inflammation/activity.
Symptoms
-
Early fibrosis usually causes no symptoms.
-
Fibrosis is often called "silent" for this reason.
-
Symptoms typically appear only at advanced stages.
-
Fatigue can occur as fibrosis advances.
-
Advanced disease can cause jaundice, swelling, and confusion.
-
Easy bruising can signal advanced liver dysfunction.
-
Many people have significant fibrosis yet feel completely well.
Diagnosis & Testing
-
Fibrosis is assessed with blood tests, imaging, and sometimes biopsy.
-
FIB-4 is a simple blood-based fibrosis risk score.
-
The APRI score uses AST and platelets to estimate fibrosis.
-
The ELF test is a blood panel measuring scarring markers.
-
FibroScan (transient elastography) measures liver stiffness.
-
Stiffer livers generally indicate more fibrosis.
-
MR elastography is a highly accurate imaging method for fibrosis.
-
Ultrasound can suggest chronic liver changes but doesn't stage fibrosis precisely.
-
Liver biopsy remains the gold standard for staging.
-
A biopsy reveals the exact stage and pattern of scarring.
-
Noninvasive tests increasingly reduce the need for biopsy.
-
Fibrosis test results can be affected by other factors, so context matters.
Complications
-
Advanced fibrosis can progress to cirrhosis.
-
Cirrhosis is largely irreversible, though progression can be slowed.
-
Portal hypertension is a key complication of advanced scarring.
-
Ascites (fluid buildup) can result from advanced fibrosis.
-
Variceal bleeding is a serious complication of portal hypertension.
-
Hepatic encephalopathy (confusion) can occur with advanced disease.
-
Advanced fibrosis and cirrhosis raise liver cancer risk.
-
The most severe fibrosis can lead to liver failure.
-
Higher fibrosis stages are associated with higher mortality.
Reversibility & Management
-
Earlier-stage fibrosis can improve when the underlying cause is treated.
-
Curing hepatitis C can lead to fibrosis regression.
-
Stopping alcohol can improve alcohol-related fibrosis, especially early on.
-
Losing 7–10% of body weight can improve fibrosis in metabolic fatty liver.
-
Good diabetes and metabolic control support fibrosis improvement.
-
The Mediterranean diet has strong evidence in metabolic liver disease.
-
Resmetirom (Rezdiffra) was FDA-approved in 2024 for MASH with fibrosis.
-
Many additional anti-fibrotic drugs are in clinical trials.
-
Hepatitis A and B vaccines help protect an already-injured liver.
-
At the cirrhosis stage, regular liver cancer screening is recommended.
-
Early detection offers the best chance to reverse or halt fibrosis.